Literature DB >> 35976484

The Advantages, Challenges, and Future of Human-Induced Pluripotent Stem Cell Lines in Type 2 Long QT Syndrome.

Dihui Cai1, Zequn Zheng1,2, Xiaojun Jin1, Yin Fu1, Lichao Cen1, Jiachun Ye1, Yongfei Song3, Jiangfang Lian4,5.   

Abstract

Type 2 long QT syndrome (LQT2) is the second most common subtype of long QT syndrome and is caused by mutations in KCHN2 encoding the rapidly activating delayed rectifier potassium channel vital for ventricular repolarization. Sudden cardiac death is a sentinel event of LQT2. Preclinical diagnosis by genetic testing is potentially life-saving.Traditional LQT2 models cannot wholly recapitulate genetic and phenotypic features; therefore, there is a demand for a reliable experimental model. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) meet this challenge. This review introduces the advantages of the hiPSC-CM model over the traditional model and discusses how hiPSC-CM and gene editing are used to decipher mechanisms of LQT2, screen for cardiotoxicity, and identify therapeutic strategies, thus promoting the realization of precision medicine for LQT2 patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gene editing; Human-induced pluripotent stem cells; KCNH2; Precision medicine; Type 2 long QT syndrome

Year:  2022        PMID: 35976484     DOI: 10.1007/s12265-022-10298-x

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   3.216


  98 in total

1.  Postmortem long QT syndrome genetic testing for sudden unexplained death in the young.

Authors:  David J Tester; Michael J Ackerman
Journal:  J Am Coll Cardiol       Date:  2006-12-29       Impact factor: 24.094

2.  Prevalence of the congenital long-QT syndrome.

Authors:  Peter J Schwartz; Marco Stramba-Badiale; Lia Crotti; Matteo Pedrazzini; Alessandra Besana; Giuliano Bosi; Fulvio Gabbarini; Karine Goulene; Roberto Insolia; Savina Mannarino; Fabio Mosca; Luigi Nespoli; Alessandro Rimini; Enrico Rosati; Patrizia Salice; Carla Spazzolini
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

Review 3.  Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Karim Sallam; Yingxin Li; Philip T Sager; Steven R Houser; Joseph C Wu
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

Review 4.  Long-QT syndrome: from genetics to management.

Authors:  Peter J Schwartz; Lia Crotti; Roberto Insolia
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-08-01

5.  Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment?

Authors:  Nynke Hofman; Hanno L Tan; Marielle Alders; Irene M van Langen; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2010-06-08       Impact factor: 24.094

6.  Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias.

Authors:  Q Wang; M E Curran; I Splawski; T C Burn; J M Millholland; T J VanRaay; J Shen; K W Timothy; G M Vincent; T de Jager; P J Schwartz; J A Toubin; A J Moss; D L Atkinson; G M Landes; T D Connors; M T Keating
Journal:  Nat Genet       Date:  1996-01       Impact factor: 38.330

7.  SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome.

Authors:  Q Wang; J Shen; I Splawski; D Atkinson; Z Li; J L Robinson; A J Moss; J A Towbin; M T Keating
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

8.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.

Authors:  M E Curran; I Splawski; K W Timothy; G M Vincent; E D Green; M T Keating
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

Review 9.  Modifier genes for sudden cardiac death.

Authors:  Peter J Schwartz; Lia Crotti; Alfred L George
Journal:  Eur Heart J       Date:  2018-11-21       Impact factor: 35.855

Review 10.  Human iPSC-Derived Cardiomyocytes for Investigation of Disease Mechanisms and Therapeutic Strategies in Inherited Arrhythmia Syndromes: Strengths and Limitations.

Authors:  Simona Casini; Arie O Verkerk; Carol Ann Remme
Journal:  Cardiovasc Drugs Ther       Date:  2017-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.